Heuro Canada First to Bring Revolutionary Neurological Health Technology to Canada

CBJ Newsmakers

Leader in traumatic brain injury management aims to change how Canadians address their neurological health

SURREY, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) — Heuro Canada Inc., a leading provider of innovative neurological health solutions, is championing a new therapeutic paradigm for individuals experiencing neurological symptoms in clinics across Canada.

Heuro Canada is launching a new revolutionary, non-invasive treatment program at its newly opened Neurotherapy Montreal, Canada’s first clinic to feature the highly anticipated PoNS neurotechnology from U.S.-based Helius Medical Technologies. They have plans to open their second location, the Surrey Neuroplasticity Clinic in Surrey, B.C., in January 2019 with others to follow in major urban areas across Canada.

Helius Medical Technologies’ Health Canada-approved PoNS (Portable Neuromodulation Stimulator) neurotechnology can provide powerful therapy to clients experiencing persistent balance deficits, from past mild to moderate traumatic brain injuries, when combined with physical or cognitive therapy. The PoNS device is the first non-invasive means for delivering neurostimulation through the tongue, and is designed to amplify the brain’s powerful ability to heal itself.

Rudi van den Broek, Managing Director of Heuro Canada, says the technology can help many Canadians manage balance disorder in a non-invasive way.

“The PoNS technology offers a transformative treatment experience for balance symptoms from previous mild to moderate traumatic brain injuries,” he says. “By combining physical or cognitive therapy with innovative neurotechnologies, successful treatment is possible and can help Canadians maximize their potential and overall wellness.”

Nicole Strachan, clinical lead for Heuro Canada, says the new comprehensive treatment plan, which spans 16 weeks, focuses on each client’s personal rehabilitation.

“Each therapeutic plan is highly individualized to the needs of the client,” she says, “making it possible for Canadians to manage their neurological symptoms and improve their overall quality of life.”

The grand opening of Neurotherapy Montreal is Friday, December 7th at 5:30 p.m.

Heuro Canada is continuing to deploy the Heuro Program in licensed clinics across Canada, as part of its broader goal to offer innovative treatment programming that helps Canadians restore their livelihood and overcome persistent deficiencies, such as gait and balance, from past brain injuries.

Heuro Canada Inc. is a leading provider of innovative and transformative neurological health assessment and treatment technologies and solutions. With few viable therapeutic options currently available for managing and treating the neurological symptoms associated with traumatic brain injuries, Heuro is championing a new treatment paradigm that helps individuals experiencing persistent deficits, particularly with gait and balance, to restore their livelihood and overcome past moderate traumatic brain injuries. Heuro Canada’s Neurotherapy Montreal clinic is the country’s first clinic to offer the Helius Medical Technology PoNS therapy, with a second location opening in 2019 – the Surrey Neuroplasticity Clinic in Surrey, B.C.

Website: https://heuro.ca
LinkedIn: Heuro Canada
Twitter: @HEUROCanada
Instagram: @heurocanada

The Portable Neuromodulation Stimulator (PoNS) by U.S.-based Helius Medical Technologies is a Class II Medical Device cleared for commercial distribution in Canada and an investigational, non-invasive, medical device currently under review by the United States Food and Drug Administration for clearance to improve balance in patients following a mild-to-moderate traumatic brain injury (mTBI) when combined with targeted physical therapy. PoNS Treatment is the first and only tongue-delivered neuromodulation treatment being developed to combine stimulation of cranial nerves with physical and cognitive therapy to restore lost neurological function.

For media inquiries, please contact:
Holly Featherstone